A novel recombinant baculovirus expression vector was used to produce His-tagged human transferrin in a transformed insect cell line (Tn5b4GalT) that constitutively expresses a mammalian b-1,4-galactosyltransferase. This virus encoded the His-tagged human transferrin protein in conventional fashion under the control of the very late polyhedrin promoter. In addition, to enhance the synthesis of galactosylated biantennary N-glycans, this virus encoded human b-1,2-N-acetylglucosaminyltransferase II under the control of an immediate-early (ie1) promoter. Detailed analyses by MALDI-TOF MS, exoglycosidase digestion, and two-dimensional HPLC revealed that the N-glycans on the purified recombinant human transferrin produced by this virus±host system included four different fully galactosylated, biantennary, complex-type glycans. Thus, this study describes a novel baculovirus±host system, which can be used to produce a recombinant glycoprotein with fully galactosylated, biantennary N-glycans.
Introduction
The baculovirus expression vector (BEV) system is widely used for the production of recombinant glycoproteins. Unlike mammalian cells, however, established insect cell lines are generally incapable of synthesizing terminally sialylated, complex-type N-glycans. The N-glycans of glycoproteins produced by insect cells consist principally of high mannose and paucimannosidic structures (Altmann et al., 1999; Marchal et al., 2001; Marz et al., 1995) . The inability of insect cells to produce mammalian-type N-glycans may be attributed to the lack of significant endogenous b-1, 4-galactosyltransferase (b4GalT; Butters and Hughes, 1981; Hollister et al., 1998; van Die et al., 1996) , b-1,2-Nacetylglucosaminyltransferase II (GlcNAcT-II; Altmann et al., 1993) , sialyltransferase (Butters and Hughes, 1981; Hooker and James, 1998; Lopez et al., 1999) , neuraminic acid synthase (Lawrence et al., 2000) , and CMP-neuraminic acid synthase activities . These deficiencies can be rectified by the addition of genes encoding the required enzymes.
Recently, four transgenic insect cell lines derived from established Spodoptera frugiperda (Sf9; Vaughn et al., 1977) or Trichoplusia ni (Tn-5B1-4, also known as High Five; Wickham et al., 1992) cell lines were described: Sfb4GalT cells (Hollister et al., 1998) and Tn5b4GalT cells (Breitbach and Jarvis, 2001 ) stably expressing mammalian b4GalT; Sfb4GalT/ST6 cells (Hollister and Jarvis, 2001 ) and Tn5b4GalT/ST6 cells (Breitbach and Jarvis, 2001 ) stably expressing b4GalT and a-2,6-sialyltransferase. Previous studies using lectin blotting and high-performance anionexchange chromatography with pulsed amperometric detection (HPAEC-PAD) analyses demonstrated that stable expression of b4GalT and a-2,6-sialyltransferase in Sfb4GalT/ST6 cells led to terminal galactosylation and sialylation of the N-glycans on baculoviral and heterologous glycoproteins (Hollister and Jarvis, 2001) . It was also demonstrated that transient coexpression of a mammalian b4GalT by infection of Tn-5B1-4 cells with an immediateearly BEV (Jarvis and Finn, 1996) led to higher terminal galactosylation and lower amounts of paucimannosidic N-glycans on human transferrin (Ailor et al., 2000) .
Interestingly, the terminal galactose was always found on the GlcNAcb(1,2)Mana(1,3)Manb branch of the elongated N-glycans produced by these virus±host systems. The inability of these systems to galactosylate the Mana(1,6) branch appeared to be related to the general absence of terminal GlcNAc on this same branch. In fact, Ailor and colleagues (2000) found that less than 1% of all the N-glycans from recombinant human serum transferrin (hTf) had a terminal GlcNAc residue on the Mana(1,6) branch. Therefore, we created a novel baculovirus±host system designed to provide the glycosyltransferase activities needed to elongate the Mana(1,6) branch of N-glycans by the addition of both N-acetylglucosamine and galactose. This system consists of Tn5b4GalT cells, which constitutively express a stably integrated bovine b4GalT cDNA (Breitbach and Jarvis, 2001) , and Ac10KIEGnTII-hTfHIS, a novel BEV that encodes human GlcNAcT-II under the control of the ie1 promoter and a His-tagged form of hTf under the control of the polyhedrin promoter. Using this system, both transferase genes were expressed during the early stages of infection, and the hTf gene was expressed during the very late stage of infection. The recombinant glycoprotein produced by this system was purified, and its major N-glycans were isolated and analyzed using a two-dimensional highperformance liquid chromatography (HPLC) mapping technique (Tomiya et al., 1988) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). The results demonstrated that the novel virus±host system described in this study could elongate the Mana(1,6) branch and produce biantennary N-glycans terminating with galactose on both branches.
Results

Construction and characterization of Ac10KIEGnTII-hTfHIS
The novel BEV used in this study was designed to express recombinant human GlcNAcT-II during the early phase and His-tagged transferrin during the very late phase of infection, so that the former enzyme activity would be available to modify the N-glycans of the latter. This virus was created in a series of steps, the first of which involved placing the human GlcNAcT-II (Tan et al., 1995) and His-tagged transferrin cDNAs under the transcriptional control of the ie1 and polyhedrin promoters, respectively. Selected steps in the construction of the ie1-GlcNAcT-II transfer plasmid are shown in Figure 1 and a detailed explanation is given in Materials and methods.
The resulting transfer plasmid was used to introduce the ie1-GlcNAcT-II gene into the p10 region of Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) and produce an intermediate virus called Ac10KIEGnTII. The genetic structure of this virus was confirmed by Southern blotting and polymerase chain reaction (PCR) analyses, as described in Materials and methods. In addition, one-step growth curve experiments were performed to determine if deletion of the p26 and p10 genes from Ac10KIEGnTII adversely influenced its in vitro replication. The results showed that the in vitro growth curves of Ac10KIEGnTII and wild-type AcMNPV were virtually identical (data not shown ). Finally, the ability of Ac10K-IEGnTII to express the GlcNAcT-II gene and induce this activity in cultured insect cells was examined, as described in Materials and methods.
Ac10KIEGlcNAcTII clearly expressed the gene and induced GlcNAcT-II activity, with a plateau at about 24 h, which was maintained until at least 72 h postinfection ( Figure 2 ). There was no detectable GlcNAcT-II activity in AcMNPV-infected insect cells, as the apparent activity observed in these cells was not significantly higher than the background of the assay, which was established using boiled cell lysates (data not shown). Subsequently, a polyhedrin-driven Escherichia coli LacZ gene and two additional Bsu36I sites were introduced into the polyhedrin region of Ac10KIEGnTII. Then the polyhedrin-driven His-tagged human transferrin gene was introduced into the polyhedrin region of the resulting virus to produce Ac10KIEGnTII-hTfHIS, which was the final BEV used for this study.
The results of our analyses of Ac10KIEGnTII, together with the results of Southern blotting, PCR, and biochemical analyses of Ac10KIEGlcNAcTII-hTfHIS, demonstrate that the new BEV used in this study encodes GlcNAcT-II activity, which is expressed before and during the very late phase of infection (about 24±72 h postinfection), and the His-tagged hTf protein, which is expressed only during the very late phase of infection (Figure 2 and data not shown). Fig. 1 . Construction of an immediate early transfer plasmid for insertion of genes into the AcMNPV p10 region. This figure shows selected steps in the construction of one of the transfer plasmids used to create Ac10KIEGnTII-hTfHIS. Additional details are given in Materials and methods. Fig. 2 . GlcNAcT-II activity in AcMNPV-(°) or Ac10KIEGnTII-(*) infected insect cells. Samples were taken from insect cell cultures infected with each virus at various times postinfection, extracted, and used for GlcNAcT-II activity assays, as described in Materials and methods.
Expression of recombinant hTf in transgenic insect cells A previously described transgenic insect cell line, Tn5b4GalT (Breitbach and Jarvis, 2001) , was used as the host for the production of recombinant hTf by TnAc10K-IEGnTII-hTfHIS. This cell line is a stably transformed derivative of Tn-5B1-4 (Wickham et al., 1992) and contains genomic copies of a bovine b4GalT gene, which is constitutively expressed under ie1 control. Thus, the novel aspect of this study was the development and use of a new BEV±host system designed to provide elevated levels of two glycosyltransferase activities necessary for the production of biantennary N-glycans. The hTf protein encoded by Ac10KIEGnTII-hTfHIS was engineered with a carboxyterminal tag consisting of the V5 epitope and six histidine residues to facilitate its purification. At 60 h postinfection, the growth medium of the Ac10KIEGnTII-hTfHISinfected Tn5b4GalT cells contained approximately 7 mg/L recombinant hTf. This product was isolated by multiple chromatography steps to apparent homogeneity.
Monosaccharide composition of recombinant hTf expressed in Tn5b4GalT cells infected with Ac10KIEGnTII-hTfHIS The monosaccharide composition of the purified recombinant hTf revealed that the glycans isolated from the hTf produced by Tn5b4GalT cells infected with Ac10KIEGlc-NAcTII-hTfHIS contained significantly higher amounts of GlcN (7.7 versus 3.2 mol/mol) and Gal (3.4 versus 0.7 mol/ mol), as compared to the hTf produced by untransformed Tn-5B1-4 cells infected with a conventional BEV, which included no mammalian glycosyltransferase genes (Table I) . These large increases in Gal and GlcN content were not observed with His-tagged hTf from Tn-5B1-4 cells (data not shown), indicating that the addition of the hexa-histidine tag was not responsible for the differences in monosaccharide compositions. The data also indicate that both of the two potential N-glycosylation sites in hTf (Asn 413 and Asn 611 ) were efficiently glycosylated.
Detailed structural analysis of the N-glycans from recombinant hTf produced by Ac10KGnTII-hTfHISinfected Tn5b4GalT cells Recombinant hTf was isolated from the growth medium of Ac10KIEGnTII-hTfHIS-infected Tn5b4GalT cells, and N-glycans were released with glycoamidase A (from sweet almond). The released N-glycans were reductively aminated with 2-aminopyridine and the pyridilamino (PA)-glycans were analyzed first by reversed-phase HPLC (Figure 3) . Each of the separated fractions from the reversed-phase column (A through Q) was then resolved by normal-phase HPLC using an amide-silica column. The results from the two columns generated a 2D map of the PA-glycans from recombinant hTf (Figure 4 ). Five major peaks designated E H , F H , J H , L H , and Q H were observed using fractions E, F, J, L, and Q from the first column (Figure 4) (Ailor et al., 2000) . Fig. 3 . HPLC elution profiles of PA-glycans derived from recombinant hTf expressed by Tn5b4GalT cells infected with Ac10KIEGnTII-hTfHIS. N-glycans were prepared from purified hTf, derivatized, and separated on the ODS-silica column as described in Materials and methods. The arrows indicate the elution positions of reference PA-glycans. Peaks E, J, and Q were coincidental with the reference PA-glycans IX, VII, and VIII (Table III) Structural characterization of PA-glycans using a 2D mapping technique A 2D mapping technique (Tomiya et al., 1988) was employed to identify the detailed structures of major N-glycans. PA-glycans E H , F H , J H , L H , and Q H were sequentially digested with b-galactosidase, b-N-acetylhexosaminidase, and a-L-fucosidase, and the products of each digestion were analyzed by HPLC on ODS and Amide-80 columns. The elution positions (expressed as glucose units, GU) of the intact and enzyme-treated PA-glycans were then plotted on a 2D map ( Figure 5 ) and compared with those of authentic reference PA-glycans.
The coordinates of intact PA-glycan E H coincided with reference PA-glycan IX (Table III) . The elution position of this glycan did not change by sequential exoglycosidase digestion with b-galactosidase, b-N-acetylhexosaminidase, and a-L-fucosidase. These results support the results from MALDI-TOF MS (Table II) and the proposed structure for PA-glycan E H shown in Table III . The coordinates of intact PA-glycan J H were coincidental with those of reference PA-glycan VII (Table III) . The b-galactosidase digestion product of PA-glycan J H coincided with reference PA-glycan V, and the b-N-acetylhexosaminidase digestion product was indistinguishable from reference PA-glycan III. Therefore, PA-glycan J H is the digalactosylated, biantennary N-glycan shown in Table III .
The coordinates of intact PA-glycan Q H coincided with those of reference PA-glycan VIII. b-galactosidase digestion altered the coordinates to match those of reference PA-glycan VI, and subsequent digestion with b-N-acetylhexosaminidase generated a product PA-glycan indistinguishable from reference PA-glycan IV. Subsequent digestion with a-L-fucosidase yielded a product that coincided with the reference trimannosyl core PAglycan III. These results indicate that PA-glycan Q H is a digalactosylated, biantennary N-glycan containing a1-6-linked Fuc, as shown in Table III .
The coordinates of PA-glycan F H (8.2 GU on ODS and 7.8 GU on amide-silica) did not correspond to any reference PA-glycan (Tomiya and Takahashi, 1998) . After sequential digestion with b-galactosidase and b-N-acetylhexosaminidase, the product coordinates coincided with those of reference PA-glycan II (Table III) . This result indicates that PA-glycan F H has the core structure II in Table III . Fuca(1-3)GlcNAcb-Asn is known to be more difficult to cleave with a-L-fucosidase than Fuca-(1-6)GlcNAcbAsn- (Takahashi et al., 1999) . However, digestion of PA-glycan F H with a large amount of a-L-fucosidase (100 mU, 20 h at 37 C) yielded a product with the same coordinates as PA-glycan J H and reference PA-glycan VII. These results indicate that PA-glycan F H has the structure shown in Table III . Like PA-glycan F H , PA-glycan L H also had unique coordinates on the 2D map, with no corresponding reference PAglycan. After sequential digestion with b-galactosidase and b-N-acetylhexosaminidase, the product coordinates coincided with those of reference PA-glycan I. This indicates that PA-glycan L H has the core structure I shown in Table III . Subsequent digestion with a-L-fucosidase (20 mU, 20 h at 37 C) generated a secondary product that coincided with reference PA-glycan II. In addition, digestion of PA-glycan L H with a large amount of a-L-fucosidase (100 mU, 20 h at 37 C) generated a new product identical to reference PA-glycan VII. These results indicate that PA-glycan L H is identical to PA-glycan J H , but also has both a1-3Fuc and a1-6Fuc. ; 100 mU, ), their 2D map coordinates were compared to those of authentic reference PA-glycans I±VIII (Table III) . The arrows indicate the change in direction of the coordinates of the PA-glycans. The elution positions (as GU) of PA-glycans on ODS and amide-80 columns were determined using the analytical conditions described previously (Nakagawa et al., 1995) .
Each of the structural assignments for PA-glycans E H , F H , J H , L H , and Q H presented were completely consistent with the results of the MALDI-TOF MS analyses. Table III summarizes the structures of the five major N-glycans isolated from the recombinant hTf expressed by Ac10KIEGntII-hTfHIS-infected Tn5b4GalT cells and shows the relative abundance of each species as molar percentages of the total N-glycans.
Discussion
Previously we have reported that the recombinant hTf produced by Tn-5B1-4 cells coinfected with AcNPV-hTf, which encodes hTf under polyhedrin control, and AcP()IE1GalT, which encodes bovine mammalian b4GalT under ie1 control, contained 62% high-mannose glycans (Man 5±9 GlcNAc 2 ), 18% paucimannosidic glycans, Table III . Structures of N-glycans of recombinant hTf produced by Ac10KIEGnTII-hTfHIS-infected Tn5b4GalT cells a G, Gal; M, Man; GN, GlcNAc; F, Fuc; PA, pyridylamino.
Expression of complex-type N-glycans in insect cells and 16% incomplete complex-type glycans (Ailor et al., 2000) . Detailed glycan structural analyses revealed that 16% of the total N-glycans identified in this previous study had GlcNAcb(1,2) on the Mana(1,3) branch and 80% of the GlcNAc residues on this branch were galactosylated. In contrast, only 0.7% of the N-glycans had GlcNAcb(1,2) on the Mana(1,6) branch, despite the availability of a substantial amount of acceptor substrate for GlcNAcT-II. Because Tn-5B1-4 cells have a high level of UDP-GlcNAc , the low level of GlcNAc addition to the Mana(1,6) branch appeared to be due to a limitation in GlcNAcT-II activity in T. ni insect cells.
In the present study, Tn5b4GalT cells were used as the host for the production of His-tagged hTf under the control of the polyhedrin promoter following infection with a novel BEV called Ac10KIEGnTII-hTfHIS. Tn5b4GalT cells constitutively express a stably integrated mammalian b4GalT gene (Hollister and Jarvis, 2001 ). Ac10KIEGnTII-hTfHIS was engineered to express a mammalian GlcNAcT-II gene during the immediate early phase of infection to promote the addition of GlcNAc to the Mana(1,6) arm of N-glycans on the recombinant His-tagged hTf produced during the very late phase of infection. Because it is known that Tn-5B1-4 cells are known to add fucose through both a-1,3 and a-1,6 linkages (Ailor et al., 2000; Hsu et al., 1997) , and that glycoamidase A, but not PNGase F, is able to remove glycans containing fucose with the a-1,3 linkage (Altmann et al., 1995a; Fan and Lee, 1997) , structural analyses were performed on the N-glycan mixture released with glycoamidase A. The 2D mapping and MALDI-TOF MS data revealed the presence of a single high-mannose N-glycan species (17%), as well as four complex-type N-glycans (52%; Table III ). The characteristics of N-glycan processing in Ac10KIEGnTII-hTfHISinfected Tn5b4GalT cells are summarized later and illustrated in Figure 6 .
Processing of high-mannose N-glycans Aside from Man 5 GlcNAc 2 , the main high-mannose type glycan, only small amounts (each less than 2%) of Man 6±9 GlcNAc 2 structures were detected by 2D HPLC (data not shown). Because paucimannosidic and complex N-glycans are generated from Man 5 GlcNAc 2 , the total amount of these glycans plus Man 5 GlcNAc 2 (more than 70%) represents the total flux into pathway P2 in Figure 6 . These results demonstrate that Tn5b4GalT cells can efficiently process high-mannose N-glycans (pathway 1) to generate the acceptor substrate (Man 5 GlcNAc 2 ) for endogenous b-1,2-N-acetylglucosaminyltransferase I (GlcNAcT-I).
Addition of GlcNAc to the Mana(1,3) branch by GlcNAcT-I and processing by a-mannosidase II The four major complex-type N-glycans detected in this study, which accounted for 52% of the total N-glycans, all had GlcNAc on the Mana (1,3) arm. This result indicates that Tn5b4GalT cells have significant levels of endogenous GlcNAcT-I activity. Even so, 17% of the total N-glycans were unprocessed Man 5 GlcNAc 2 . Thus, although the endogenous GlcNAcT-I activity may indeed be substantial, this processing step may ultimately represent a bottleneck in Tn5b4GalT cells.
N-acetylglucosaminylation of Mana(1,6) arm by GlcNAcT-II The product N-glycan in the P3 processing step (Scheme 1), could serve as substrate for several enzymes (GlcNAcT-II, b4GalT, core a-1,3-fucosyltransferase [Fuc-T C3], core a-1,6-fucosyltransferase [Fuc-T C6], and b-N-acetylglucosaminidase). In the present study, we found that 52% of the total hTf N-glycans had GlcNAcb(1,2) on the Mana(1,6) branch, which was more than 70-fold (52% versus 0.7%) higher than that observed on hTf in the previous study (Ailor et al., 2000) . Thus, the ability of the novel BEV described in this study to express GlcNAcT-II clearly allowed utilization of endogenous UDP-GlcNAc and the production of biantennary, complex N-glycans. This result indicates that both GlcNAcT-II and UDP-GlcNAc are localized in sufficient quantities in the correct subcellular compartment (i.e., trans-Golgi).
Galactosylation of terminal GlcNAc
The major biantennary N-glycans were digalactosylated (Table III) , and only small amounts of partially or nongalactosylated N-glycans were observed by 2D HPLC analyses (data not shown). This suggests that Tn5b4GalT cells have high levels of both b4GalT activity and UDP-Gal in the proper subcellular compartment (i.e., trans-Golgi) to enable complete galactosylation of newly synthesized Fig. 6 . Proposed N-glycan processing pathway in Ac10KIEGnTII-hTfHIS-infected Tn5b4GalT cells. The four N-glycans in the box can be the substrates for GalT, GlcNAcT-II, Fuc-T C3, Fuc-T C6, and b-N-acetylglucosaminidase. Symbols: ¥, GlcNAc; *, mannose; *, galactose;^, fucose; ¤, glucose; R, sialic acid. Scheme 1. The product N-glycan in the P3 processing pathway.
glycoproteins. Indeed, we have observed that Tn-5B1-4 cells have significant levels of UDP-Gal and that a green fluorescent protein±tagged version of bovine b4GalT colocalizes with a trans-Golgi marker (Kawar and Jarvis, 2001 ).
Fucosylation
It is known that many insect cells contain both core Fuc-T C3 and core Fuc-T C6 activities, although expression levels vary in different cell lines (Altmann et al., 2001; Staudacher and Marz, 1998) . Both core Fuc-T's require an acceptor substrate with GlcNAcb(1,2) on the Mana(1,3) arm (Staudacher and Marz, 1998) . These enzymes can modify N-glycans to generate three types of fucosylated N-glycans, all of which were found in the present study (Table III) . This indicates that Tn5b4GalT cells have both Fuc-T C3 and Fuc-T C6 activities.
Generation of paucimannosidic structures
Some insect cells have a b-N-acetylglucosaminidase specific for the terminal GlcNAc on the Mana(1,3) branch, which is thought to be responsible for production of the paucimannosidic N-glycans often found on insect cell expressed glycoproteins (Altmann et al., 1995b; Licari et al., 1993) . Previous studies demonstrated that galactosylation of the GlcNAcb(1,2)Mana(1,3) arm protects the terminal GlcNAc from the action of this enzyme and suppresses the production of paucimannosidic glycans. (Ailor et al., 2000) . However, as much as 18% of the N-glycans isolated from hTf produced by AcP()IEGalT-infected Tn-5B1-4 cells were still paucimannosidic structures, and those N-glycans represented about 50% of the total of both incomplete complex-type and paucimannosidic N-glycans. In contrast, the relative amounts of paucimannosidic glycans observed in this study, such as structures I, II, III, and IV in Table III , were much less than the amounts of complex-type N-glycans. This observed decrease in paucimannosidic structures and concomitant increase of the galactosylated, biantennary complex-type N-glycans probably reflected more efficient galactosylation and protection from the b-N-acetylglucosaminidase. This is because the virus±host system used in this study involved infection of transgenic cells, in which the b4GalT gene was integrated into the chromosome with a single virus.
Sialylation
No significant levels of sialylated species were observed in this study when the released glycans were analyzed by HPAEC-PAD (data not shown). Like other insect cell lines, the sialylation potential of Tn5b4GalT cells is clearly far below that required to efficiently synthesize terminally sialylated, complex N-glycans. This could be due to limitations in the endogenous levels of sialyltransferase activity (Hooker and James, 1998; Lopez et al., 1999) and/or CMPsialic acids (Hooker et al., 1999; Lawrence et al., 2001; Tomiya et al., 2001) in Tn5b4GalT cells.
Conclusion
This study describes a novel baculovirus±host cell system and shows that the use of this system resulted in the production of a recombinant human glycoprotein with significant levels of digalactosylated, biantennary, complex N-glycans. The efficient production of digalactosylated, biantennary N-glycans in this system was achieved by (1) efficient processing of high-mannose N-glycans to produce the acceptor substrate for GlcNAcT-I; (2) protection of GlcNAcb(1,2) on the Mana(1,3) branch by galactosylation, which suppressed the production of paucimannosidic structures; (3) increased production of GlcNAcT-II activity by the expression of a mammalian GlcNAcT-II gene during the immediate-early phase of infection; and (4) increased production of b4GalT activity by expression of the integrated mammalian transgene in the Tn5b4GalT cells.
Materials and methods
Materials
The following materials were obtained from the sources Reference PA-glycans The PA-derivatives of isomalto-oligosaccharides (4±20 glucose residues) were prepared from an acid hydrolysate of dextran. PA-derivatized reference glycan I was prepared from hTf expressed by Tn-5B1-4 cells (Ailor et al., 2000) . PA-derivatized reference glycan II was prepared from reference PA-glycan I by partial digestion with a-L-fucosidase.
Other PA-derivatized reference glycans III±XIII were prepared as described previously (Tomiya et al., 1988) . The structures of the reference PA-glycans used in this study are shown in Table III .
Plasmid constructions pAc10KIEGnTIIDBsu-repaired is a baculovirus transfer plasmid in which a human GlcNAcT-II cDNA (Tan et al., 1995) is positioned under the transcriptional control of the AcMNPV ie1 promoter (Guarino and Summers, 1987) and hr5 enhancer (Guarino et al., 1986 ) and the chimeric ie1-hr5-GlcNAcT-II gene is embedded within sequences derived from the p10 region of the AcMNPV genome (Ayres et al., 1994) . This plasmid was constructed through a series of steps (Figure 1 ) that began with replacement of the EcoRV-BamHI fragment of pAcAS2 (Vlak et al., 1990) with an EcoRV-BamHI fragment from pIE1HR3 to produce pAc10KIETV. In parallel, sitedirected mutagenesis (Transformer kit; Clonetech Laboratories, Palo Alto, CA; Deng and Nickoloff, 1992) was used to introduce a silent mutation into pHG30 (Tan et al., 1995) to eliminate a Bsu36I site in the human GlcNAcT-II sequence. The mutated sequence was then PCR-amplified from the resulting plasmid, pHGNTIIDBsu, using sense (5 H -TTACTAGTGGAGACCATGAGGTTCCGCATC-3 H ) and antisense (5 H -CCACTAGTGAAACCAGTTCC-TAAACTC-3 H ) primers that added SpeI sites to its 5 H and 3 H ends. The 1.44 kb amplification product was gel-purified and cloned into pCR 2.1 TOPO (Invitrogen, Carlsbad, CA), then excised with SpeI, gel-purified, and subcloned into the unique SpeI site downstream of the ie1 promoter in pAc10KIETV, producing pAc10KIE-GnTIIDBsu. Sequencing revealed that the GlcNAcTIIDBsu fragment in this plasmid contained one PCR error. Therefore, an internal KpnI-AvrII fragment containing this mutation was excised and replaced with the corresponding fragment from pHGNTIIDBsu, which contained no mutations, to produce the final baculovirus transfer plasmid, pAc10KIE-GnTIIDBsu-repaired. Another baculovirus transfer plasmid constructed for this study, pAcP(-)TCBlue, has a polyhedrin-driven gene encoding a fusion protein composed of an N-terminal fragment of polyhedrin and an enzymatically active C-terminal fragment of E. coli b-galactosidase. This construct was designed to introduce the polyhedrin-bgal fusion gene and three Bsu36I sites, including one in the essential p74 gene, into the polyhedrin region of the AcMNPV genome. Briefly, this plasmid was constructed by using site-directed mutagenesis to introduce the Bsu36I sites near the polyhedrin ATG (new sequence is 5 H -ATGCCTgAggAT-3 H , with mutations in lowercase) and the C-terminal end of the p74 open reading frame (new sequence is 5 H -TTTATAATCcTTAGGGT-3 H , with mutation in lowercase) to produce an intermediate plasmid called pAcPoly-ATG/BBR5S. A BamHI fragment encoding a large C-terminal fragment of E. coli b-galactosidase was then subcloned from pMC1871 (Shapira et al., 1983) into the unique BamHI site of pAcPoly-ATG/BBR5S to create pAcP(-)TCBlue. This last manipulation introduced the C-terminal b-galactosidase coding sequence downstream and in-frame with the sequence encoding the first 57 amino acids of polyhedrin, as well as the third Bsu36I site, which is located within the Lac Z gene.
The last baculovirus transfer plasmid constructed for this study was pBlueBac-hTfr-V5His, which encodes a His-tagged human transferrin cDNA under the transcriptional control of the AcMNPV polyhedrin promoter, embedded within sequences derived from the polyhedrin region of the viral genome. The human transferrin 2.1-kb coding region was amplified by PCR using pTfR27A (from American Type Culture Collection, a gift of J. Slavicek) as the template with the following primers: a forward primer (MB1), 5
H -CACTACTAGTCACCCGGAAGATG-AGGCTCG, which included a SpeI site (italics) upstream of the initiator ATG (underscored), and a reverse primer (MB2), 5
H -AGTG CTCGAGAGGTCTACGGAAACTG-CAGG, which included an XhoI site (italics). PCR was performed in a 100-ml reaction using the following cycle settings: 94 C for1 min; 25 cycles at 94 C for 1 min, 55 C for 1.5 min, and 72 C for 2 min; a final extension at 72 C for 10 min; and hold at 4 C. PCR reagents were purchased from Applied Biosystems (Foster City, CA), and PCR was performed using an Applied Biosystems GeneAmp 2400 thermal cycler.
After digestion with the appropriate enzyme, the PCR product was ligated into the Drosophila expression system vector pMT/V5-His A (Invitrogen) to introduce an in-frame V5 epitope and 6Â His tag, then the ligated construct was introduced into E. coli DH5-a cells. The human transferrin±V5-His coding region was shuttled from pMT/V5-His A-hTfrV5His into the baculovirus expression plasmid pBlueBac4.5 (Invitrogen) by PCR amplification using the following primers: a forward primer (MB10), 5
H -CACTGCTAGCCACCCGGAAGMATGAGGCTCG, which included a NheI restriction site (italics) upstream of the initiator ATG (underscored), and a reverse primer (MB11), AGTGAGATCTGCTGATCAGCGGGTTTA-AC, which included a BglII restriction site (italics) and terminated 23 bp past the terminal His codon. PCR amplification was performed as before except that only 12 cycles were used. The final construct, pBlueBac-hTfr-V5His, was sequenced to verify that no base changes had been introduced during PCR.
Cells and viruses
Sf9 (Vaughn et al., 1977) and Tn5b4GalT (Breitbach and Jarvis, 2001 ) cells were routinely maintained as spinner cultures in TNM-FH medium (Summers and Smith, 1987) containing 10% (v/v) fetal bovine serum (Hyclone) or in SFX-Insect serum-free medium (Hyclone). AcMNPV strain E2 (Summers and Smith, 1978) was used as the wild-type baculovirus. Ac10KIEGnTII, Ac10KIEGnTII-TCBlue, and Ac10KIEGnTII-hTfHIS are new recombinant baculoviruses that were produced for this study. Ac10KIEGnTII was isolated by crossing genomic DNA from the recombinant baculovirus AcMNPV-MO21 (Martens et al., 1995) with pAc10KIE-GnTIIDBsu-repaired. Prior to the cross, the AcMNPV-MO21 viral DNA was linearized with Bsu36I to facilitate recombination within the p10 region, as described previously (Martens et al., 1995) . Recombinant viruses were tentatively identified by dot-blot hybridization and confirmed by Southern blotting, as described previously (O'Reilly et al., 1992; Summers and Smith, 1987) . Subsequently, genomic DNA was isolated from Ac10K-IEGnTII and crossed with pAcP(-) TCBlue to produce Ac10KIEGnTII-TCBlue. This virus was tentatively identified by its occlusion-negative blue plaque phenotype in the presence of x-gal and its genetic structure was confirmed by Southern blotting.
Finally, genomic DNA from Ac10KIEGnTII-TCBlue was crossed with pAc-hTfHIS to produce Ac10KIEGn-TII-hTfHIS. The viral DNA used for this cross was linearized with Bsu36I to facilitate recombination within the polyhedrin region. The resulting recombinant virus was tentatively identified by its occlusion-negative white plaque phenotype and its genetic structure confirmed by dotblotting, Southern blotting, and PCR analyses. In addition, the ability of this virus to induce GlcNAcT-II activity and His-tagged hTf during infection was confirmed by enzyme assays, as described later, and immunoblotting, as described previously (Jarvis and Summers, 1989) . Each recombinant baculovirus used in this study was plaque purified three times, amplified at low multiplicity of infection, and titered by plaque assay in Sf9 cells, as described previously (Summers and Smith, 1987) .
GlcNAcT-II assay Sf9 cells were infected with AcMNPV or Ac10KIEGnTII at a multiplicity of about 10 PFU/cell and allowed to adsorb for 1 h at 28 C. Then the inocula were removed, and the cells were fed with complete TNM-FH and returned to the incubator. Samples were harvested at various times after infection, and the cells were washed with GlcNAcT-II buffer (0.1 M MES, pH 6.1; 0.1 M NaCl) and counted with a hemocytometer. Subsequently, the cells were pelleted and resuspended at a density of 50,000 cells/ml in GlcNAcT-II lysis buffer (0.2M MES, pH 6.1; 0.4 M GlcNAc; 20 mM AMP; 1% [v/v] Triton X-100, 0.2 M NaCl) supplemented with a protease inhibitor cocktail (Complete; Roche Molecular Biochemicals, Indianapolis, IN). The cells were freeze-thawed in this buffer to enhance lysis; then the extracts were clarified at top speed in a microcentrifuge for 15 min at 4 C, and the supernatants were harvested. The GlcNAcT-II assays were performed in a final volume of 30 ml containing 5 ml of cell lysate (equivalent to 2.5 Â 10 C, then applied to methanol-activated and waterwashed Sep-Pak C18 cartridges. The cartridges were washed extensively with water, then bound radioactivity was eluted with methanol into ScintiSafe Plus 50% scintillation cocktail (Fisher Scientific, Pittsburgh, PA) and quantified in a Beckman (Palo Alto, CA) Model LS 1801 liquid scintillation spectrometer.
One-step baculovirus growth curves Sf9 cells were pelleted by low-speed centrifugation, gently resuspended in complete TNM-FH, and infected with AcMNPV or Ac10KIEGnTII at a multiplicity of about 10 PFU/cell. The virus was allowed to absorb for 1 h at 28 C; then the inocula were removed and the cells were gently washed three times with complete TNM-FH. The cells were resuspended in complete TNM-FH, and equal aliquots were dispensed into culture flasks. After various incubation times at 28 C, the media from cells infected with each virus were harvested from triplicate flasks and pooled, and the amounts of infectious budded virus progeny in each pool were measured by plaque assays on Sf9 cells, as described previously (Summers and Smith, 1987) .
Preparation of anti-hTf-IgG-(Sepharose 4 Fast Flow) Specific antibody to hTf was isolated from an IgG fraction prepared from anti-hTf rabbit serum by using an immobilized apo-hTf column. The apo-hTf-(Sepharose 4 fast Flow) was prepared by reacting apo-hTf with N-hydroxysuccinimide-activated Sepharose 4 Fast Flow according to the manufacturer's protocols. Anti-hTf-IgG-(Sepharose 4 Fast Flow) was prepared by immobilizing the specific anti-hTf antibody using N-hydroxysuccinimideactivated Sepharose 4 Fast Flow.
Expression and purification of human transferrin Tn5b4GalT cells were grown to a density of 1 Â 10 6 cells/ml in 250 ml of SFX-Insect serum-free medium in 500-ml shake-flasks cultured at 28 C and 125 rpm. The cells were then pelleted and infected at a multiplicity of about 2±5 PFU per cell. After a 1-h absorption period, the cells were repelleted, washed twice, resuspended in fresh SFX-Insect medium, and returned to the shake-flasks. The appearance of hTf in the extracellular medium was monitored by immunoblotting and the results showed that maximal amounts of hTf, with minimal degradation, were observed at 60 h postinfection. Thus, cultures were harvested at this time point by low-speed centrifugation to obtain the cell-free supernatant. The medium (1 L) was concentrated by ultrafiltration with an Amicon stirred-cell concentrator (f 76 mm) using a YM-30 membrane (Millipore, Bedford, MA). Then proteins were precipitated by adding 62 g ammonium sulfate to the 200 ml concentrate in the cold (50% final saturation). After removing the precipitate by centrifugation at 8000 rpm for 15 min at 4 C in Sorvall SS-34 Rotor (Kendro, Newtown, CT), the recombinant hTf was precipitated by adding 48 g ammonium sulfate to 224 ml of the supernatant (80% final saturation) in the cold and collected by centrifugation using the same conditions already described. The precipitate was dissolved in buffer A (10 mM sodium phosphate, pH 7.5) and dialyzed against the same buffer at 4 C. The sample was then applied to a DEAE-(Sepharose 4 Fast Flow) column (f2.6 Â 20 cm) equilibrated with buffer A.
After washing the column with 3 column volumes of buffer A, bound proteins were eluted with a linear gradient of sodium chloride (0±0.5 M) in buffer A. Transferrincontaining fractions were identified by ELISA, pooled, the NaCl concentration was adjusted to 0.5 M, and the sample was applied to a Ni 2 -loaded iminodiacetic acid±Sepharose 6B column (f1.5 Â 6 cm) equilibrated with buffer B (50 mM sodium phosphate, pH 7.0, containing 0.5 M NaCl). The column was washed with three column volumes of buffer B, and the bound proteins were successively eluted with 5 column volumes each of buffer B containing 50 mM imidazole and buffer B containing 1 M imidazole. The recombinant hTf was recovered in both the 50 mM and the 1 M imidazole eluates in a 3:2 ratio, as determined by ELISA assay. Sodium dodecyl sulfate±polyacrylamide gel electrophoresis (SDS±PAGE) analyses showed that the 1 M imidazole eluate contained hTf with high purity, whereas the 50 mM imidazole fraction contained hTf and many other proteins. The 1 M imidazole eluate was dialyzed against distilled water and lyophilized. To obtain a total hTf preparation, recombinant hTf in the 50 mM imidazole eluate was further purified by immunoaffinity chromatography. The 50 mM imidazole eluate was dialyzed against 50 mM sodium phosphate, pH 7.0, to remove imidazole, and solid NaCl was added to a final concentration of 0.5 M. The sample was loaded onto an anti-hTf-IgG column (f1.6 Â 6 cm) equilibrated with 10 mM Tris±HCl, pH 7.0, containing 0.5 M NaCl. After unbound proteins were washed off with the same buffer, recombinant hTf was eluted with 0.1 M glycine±HCl, pH 2.7, containing 0.5 M NaCl. The eluate was immediately neutralized with 0.5 M Tris±HCl, pH 8.3, dialyzed against water, and lyophilized. Finally, the purified hTf preparations from the 1 M imidazole eluate on the immobilized metal affinity chromatography and immunoaffinity chromatography were combined and used for carbohydrate analyses.
The purity of the hTf preparation was analyzed by SDS± PAGE (10% acrylamide gels) under reducing condition, and protein was visualized by Coomassie brilliant blue R-250 staining.
ELISA assay of recombinant hTf
The concentration of recombinant hTf in all purification steps was determined with an ELISA kit for human transferrin using apo-hTf as a standard.
Monosaccharide analysis
Neutral and amino sugar content in the purified protein was determined by the methods of Fan et al. (1994) .
Preparation and derivatization of N-glycans from recombinant hTf N-glycans were prepared from the purified recombinant hTf as described previously (Ailor et al., 2000) . Briefly, a trypsin-chymotrypsin digest of htf (5 mg) was treated with glycoamidase A (0.4 mU), and the released glycans were passing the sample through a Dowex 50 Â 2 (H ) column (1 ml). The purified N-glycans were reductively aminated with 2-aminopyridine as previously described (Nakagawa et al., 1995; Yamamoto et al., 1989) , and the resulting PA-glycans were purified by gel filtration on a Sephadex G-15 column (1.0 Â 40 cm) using 10 mM NH 4 HCO 3 as the eluant.
Isolation and characterization of PA-glycans by 2D HPLC All HPLC separations were performed on an LC-10Ai HPLC system (Shimadzu USA). PA-glycans were monitored by fluorescence using e ex 300 nm and e em 360 nm. The PA-glycan mixtures were separated and characterized by 2D HPLC mapping as described previously (Nakagawa et al., 1995; Tomiya et al., 1988) . The PAglycans were successively separated on a reversed-phase column (Shim-pack CLC-ODS) and then a normal-phase column (Amide-80). An ammonium formate buffer (10 mM, pH 4.3) was used for preparative scale chromatography on the ODS column. To normalize the elution positions of PA-glycans, both HPLC columns were calibrated with PA-isomalto-oligosaccharides (4±20). A GU value for each peak was obtained by comparing the elution time of sample PA-glycan and PA-iso-maltooligosaccharides, according to standard procedures (Tomiya et al., 1988) . The elution position of each PA-glycan was mapped by plotting the elution positions (expressed in GU) on the reversed-phase and the normal-phase columns on the X-and Y-axes, respectively. The coordinates for sample PA-glycans on the 2D map were compared with those of authentic reference PA-glycans by cochromatography.
Exoglycosidase digestion
Sample and reference PA-glycans were subjected to sequential exoglycosidase digestion, and the elution positions of the digests were compared with the reference compounds on the 2D map. Each PA-glycan (100 pmol) isolated from the 2D HPLC was digested with exoglycosidases (b-galactosidase, b-N-acetylhexosaminidase, and a-L-fucosidase) under previously described conditions (Takahashi and Tomiya, 1992) . The elution coordinates of each exoglycosidasetrimmed glycan were examined on the 2D map to verify its structural identity.
MALDI-TOF MS analysis
The molecular masses of PA-glycans were determined by MALDI-TOF MS using a Voyager Elite time-of-flight mass spectrometer equipped with a delayed-extraction system (PerSeptive Biosystems, Framingham, MA). The matrix solution was prepared by dissolving 2,5-dihydroxybenzoic acid in 50% aqueous acetonitrile solution at a concentration of 10 mg/ml. The samples (approximately 300 pmol) were dissolved in the matrix solution (10 ml), and 1 ml was placed on a sample plate and vacuum-dried. The samples were ionized with a nitrogen laser at 337 nm. The data were analyzed using GRAMS/386 software. A mixture of PA-isomalto-oligosaccharides (DP 4±20) was used for calibration.
high-performance anion-exchange chromatography with pulsed amperometric detection; HPLC, high-performance liquid chromatography; hTf, human serum transferrin; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; PA, pyridylamino; PCR, polymerase chain reaction; SDS±PAGE, sodium dodecyl sulfate±polyacrylamide gel electrophoresis.
